Contact:
Howard Robin and Patti Ketchner
Sirna Therapeutics, Inc.
303-449-6500
or Justin Jackson (media)
or E. Blair Schoeb (investors)
both of Burns McClellan
212-213-0006
Sirna Therapeutics To Present at the JP Morgan Healthcare Conference
BOULDER, Co.—Jan. 12—Sirna Therapeutics Inc. (Nasdaq: RNAI) announced today that Howard W. Robin, President and Chief Executive Officer of Sirna, is scheduled to present a corporate and product update at the 22nd Annual JP Morgan Healthcare Conference on Thursday, January 15, 2004. The presentation is scheduled to take place at 11:00 am (PT) at the Westin St. Francis Hotel in San Francisco, CA.
To access the live audio broadcast or the subsequent archived recording go to the Company’s website athttp://www.sirna.com. The live broadcast will be archived for 30 days.
About Sirna Therapeutics
Sirna Therapeutics (Nasdaq: RNAI) is using its proprietary technology and expertise in nucleic acids to develop a new class of nucleic acid-based therapeutics involving RNA interference. RNAi is a mechanism used by cells to regulate the expression of genes and the replication of viruses. The RNA interference mechanism uses short interfering RNA (siRNA) to induce the destruction of target RNA using naturally occurring cellular protein machinery. Harnessing the natural phenomenon of RNAi holds potential for the development of a new class of drugs with specificity toward a wide range of diseases that result from undesirable protein production or viral replication. More information on Sirna Therapeutics is available on the Company’s web site at www.sirna.com.
This press release contains forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in the Company’s Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings. Sirna undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
